Extensive-Stage SCLC: Implications of IMpower133
Practical implications of the IMpower133 study for providers and patients.
Role of Gene Profiling Assays in Early-Stage HR+ Breast Cancer
The role of gene profiling assays in identifying candidates for chemotherapy in early HR-positive breast cancer.
The IMpower133 Trial in Extensive-Stage SCLC
Dr Mark Socinski reviews the IMpower133 trial of first-line chemotherapy plus atezolizumab in extensive-stage small cell lung cancer.
Third-Line Therapy in Follicular Lymphoma
Sameh Gaballa, MD, considers therapeutic options in the third-line setting and beyond for patients who relapse.
Tazemetostat for Relapsed/Refractory Follicular Lymphoma
Sameh Gaballa, MD, discusses molecular testing in the third-line setting and beyond, as well as the mechanism of action of tazemetostat in the treatment of relapsed/refractory follicular lymphoma.
Perioperative Decision-Making in HR+ Breast Cancer
Considerations for therapeutic decision-making in adjuvant and neoadjuvant settings in early-stage HR-positive breast cancer.
Optimizing Systemic Therapy for Early-Stage HR+ Breast Cancer
Goals and standards of care for therapy in patients with early-stage HR-positive breast cancer.
Decision Making in Selecting Treatment in HER2+ BC
Experts provide insights on clinical decision-making in the setting of patient with HER2+ breast cancer.
The Role of Prophylactic Therapy in HER2+ BC
Key opinion leaders explore the appropriateness of prophylactic therapy for brain metastases and share their thoughts on best practices.
Immunotherapy as First-Line Treatment for Extensive-Stage SCLC
The rationale for adding an immunotherapy agent to frontline therapy for extensive-stage small cell lung cancer and considerations for patient selection.
Treatment Challenges in Extensive-Stage SCLC
A review of current options for management of SCLC and the challenges of treating this population.
Medical World News® Deep Dive: Mehmet Sitki Copur, MD, on the Potential of mRNA Vaccines in Cancer Immunotherapy
Copur spoke with CancerNetwork® about the potential for a new era of cancer treatment and immunotherapy with the recent approval of mRNA vaccines to treat COVID-19.
Medical World News® After Hours: Oncologist Amy Comander, MD, Discusses Marathon Running and Motivation
During an After Hours segment of Medical World News®, Amy Comander, MD, spoke about her passion for marathon running and how it helps keep her inspired in her work as an oncologist.
Considerations for Treatment Selection in R/R FL
An expert in follicular lymphoma highlights factors to consider when choosing therapy for first relapse and how this impacts later line treatment, as well as molecular testing and MRD.
Treatment Options in Relapsed/Refractory Follicular Lymphoma
Sameh Gaballa, MD, discusses patients who relapse after frontline treatment as well as prognostic and predictive factors for relapse.
Kathryn Maples, PharmD, BCOP, on Key Considerations for Belantamab Mafodotin Administration in Multiple Myeloma
A clinical pharmacy specialist discusses what’s needed to get the REMS program set up and touches on reimbursement considerations for the administration of belantamab mafodotin in patients with multiple myeloma.
Andreana N. Holowatyj, PhD, MS, Talks AACR and the Value of the Annual Meeting 2021
Holowatyj detailed the benefits of a conference like that of the American Association for Cancer Research Annual Meeting 2021, which presents opportunities for thought leaders to come together.
Management Approaches for Patients with HER2+ BC at Risk for Brain Metastases
An expert panel of breast oncologists discusses factors they consider when deciding whether to screen a patient with HER2+ breast cancer for brain metastases.
Patient Case: A 37-Year-Old Woman With HER2+/HR- Breast Cancer
Adam Brufsky, MD, PhD, presents the case of a 37-year-old woman with HER2+/HR- metastatic breast cancer and polls the audience about screening for brain metastases.
Evolution of Therapies for SCLC
Mark Socinski, MD, of AdventHealth Cancer Institute discusses his approach to treating small cell lung cancer and reacts to advances in the treatment of extensive-stage disease.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Decision Making in Selecting Treatment in HER2+ BC")
